Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12721092 | 0.77 | MAPK1 (0.61) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL11400426 | 0.73 | CA1 (0.63) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL11400427 | 0.73 | CA1 (0.63) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL3970256 | 0.73 | MAPK1 (0.56) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL19794412 | 0.73 | MAPK1 (0.56) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL31227346 | 0.72 | MAPK1 (0.54) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL22925732 | 0.72 | MAPK1 (0.54) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL27772735 | 0.71 | MAPK1 (0.53) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL11401868 | 0.69 | NPC1 (0.45) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 | |
| SCHEMBL11401863 | 0.69 | NPC1 (0.45) | MAPK1ALDH1A1LMNAKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538084-B1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | ACETYLON PHARMACEUTICALS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-10927072-B2 | Phenyl and pyridinyl hydroxamic acids | ACETYLON PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10370324-B2 | Phenyl and pyridinyl hydroxamic acids | ACETYLON PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180127356-A1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | ACETYLON PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127356-A1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | ACETYLON PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370324-B2 | Phenyl and pyridinyl hydroxamic acids | HDAC6, HDAC1, HDAC5 | MAPK1 2026/4885ALDH1A1 497/4885LMNA 1665/4885 |
| US-10927072-B2 | Phenyl and pyridinyl hydroxamic acids | HDAC6, HDAC1, HDAC5 | MAPK1 2026/4885ALDH1A1 497/4885LMNA 1665/4885 |
| US-20180127356-A1 | PHENYL AND PYRIDINYL HYDROXAMIC ACIDS | HDAC6, HDAC1, HDAC5 | MAPK1 2026/4885ALDH1A1 497/4885LMNA 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.